Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dexamethasone suppression test in first-episode schizophrenia.

Eva Cesková1, Tomás Kaspárek, Alexandra Zourková

  • 1Department of Psychiatry, Masaryk University, Faculty of Medicine, Brno, Czech Republic. eceska@med.muni.cz

Neuro Endocrinology Letters
|August 8, 2006
PubMed
Summary

Dexamethasone test nonsuppression rates in first-episode schizophrenia fluctuate with illness stage and treatment. Short-term treatment reduces nonsuppression, but it increases at one-year follow-up, correlating with negative symptoms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Towards a more inclusive psychiatry: diversity among presenters and participants in the 25th World Congress of Psychiatry.

World psychiatry : official journal of the World Psychiatric Association (WPA)·2026
Same author

Neural correlates of social exclusion and overinclusion in patients with borderline personality disorder: an fMRI study.

Borderline personality disorder and emotion dysregulation·2023
Same author

Selected neuroendocrine factors as potential molecular biomarkers of early non-affective psychosis course in relation to treatment outcome: A pilot study.

Heliyon·2023
Same author

Therapeutic drug monitoring in psychiatry.

Casopis lekaru ceskych·2023
Same author

A preliminary choroid plexus volumetric study in individuals with psychosis.

Human brain mapping·2023
Same author

Has the utilization of serotonin receptor antagonism made an impact on schizophrenia treatment?

Expert opinion on pharmacotherapy·2022

Area of Science:

  • Neuroendocrinology
  • Psychiatry

Background:

  • Dexamethasone test (DST) nonsuppression is linked to schizophrenia symptoms.
  • No prior studies have examined DST nonsuppression in first-episode schizophrenia.

Purpose of the Study:

  • To investigate DST nonsuppression rates in first-episode schizophrenia.
  • To assess the influence of illness stage and treatment on DST nonsuppression.

Main Methods:

  • DST performed on 56 males with first-episode schizophrenia at baseline, end of acute treatment, and one-year follow-up.
  • Clinical evaluation using the Positive and Negative Syndrome Scale (PANSS).
  • Nonsuppression defined as post-dexamethasone cortisol >5 µg/dL.

Main Results:

  • DST nonsuppression rates were 18% (baseline), 5% (end of treatment), and 16% (one year).

Related Experiment Videos

  • Nonsuppression correlated with negative symptoms at treatment's end.
  • Cortisolemia levels differed significantly between admission, discharge, and one-year follow-up.

    • Conclusions:

    • DST nonsuppression in schizophrenia is influenced by illness stage and medication.
    • Impaired cortisol feedback regulation may involve different mechanisms based on illness phase.